CJC-1295 Buyer's Guide: 4 Decisions Before You Buy
Your pituitary gland does not release growth hormone in a steady stream. It fires in pulses, sharp spikes that happen mostly during deep sleep and in response to exercise, and between those spikes, levels drop back down almost to zero. That pattern matters because your pituitary gland only responds strongly to growth hormone releasing hormone, something called GHRH, when it has had time to rest between signals. Flat, continuous stimulation blunts the response. Pulses keep it sharp.
That is the whole architecture you are working with when you use a secretagogue. Not replacing growth hormone. Optimizing the system that makes it.
CJC-1295 is a synthetic version of GHRH. It binds to GHRH receptors on your pituitary and tells it to release growth hormone. Ipamorelin works through a completely separate receptor, something called GHSR1a, the ghrelin receptor, and it amplifies the signal through a different pathway. You run both together because they hit two different targets and the combined pulse is larger than either one alone. That is the mechanism. Now the four decisions matter in the context of that mechanism.
The first decision is whether to buy CJC-1295 with DAC or without it. DAC stands for Drug Affinity Complex, which is a modification that makes the peptide bind to albumin, a protein in your blood, and that binding extends the half-life from roughly 30 minutes up to about seven days. Convenient. One or two injections per week instead of daily dosing.
But here is the problem with that convenience. Seven-day half-life means seven-day flat elevation of GHRH. Not pulses. A continuous low-level signal sitting on your pituitary around the clock, which is exactly the pattern your pituitary was designed not to respond to long-term. You lose the architecture that makes the secretagogue approach different from just injecting growth hormone directly.
If you want a flat elevated baseline of growth hormone, exogenous growth hormone does that with decades of clinical trial data, precise dosing, and a known safety profile. The whole reason to choose a secretagogue is to preserve the pulsatile pattern and the feedback loop. DAC removes that reason. No DAC is the only version that does what you are actually trying to do.
The second decision is whether to buy a pre-made blend of CJC and Ipamorelin or separate vials. This is less about pharmacology and more about math. A blend simplifies the injection, one draw instead of two, but you lose the ability to adjust the ratio independently. If you are buying a blend with five milligrams of CJC and five milligrams of Ipamorelin reconstituted in two milliliters of bacteriostatic water, each 10 units on an insulin syringe delivers 250 micrograms of each peptide. Know your math before you choose a blend, because if you ever want to adjust one without the other, you will need separate vials anyway.
The third decision is cycling, and most people get the reason wrong. The common belief is that you cycle CJC-1295 because growth hormone systems in general downregulate with continuous use, and there is something correct in that general intuition, but the specific mechanism that actually forces the cycle is coming from the Ipamorelin side, not the CJC side.
Ipamorelin works through GHSR1a, the ghrelin receptor, and that receptor undergoes something called beta-arrestin mediated desensitization, which means the longer you continuously stimulate it, the more the cell pulls the receptor off its surface and reduces the total number of available receptors. Less receptors means less signal per dose. After roughly 12 to 16 weeks of continuous use, IGF-1 levels can drop 20 to 30 percent from their peak even though you are injecting the same dose you always were. The compound did not stop working. The receptor density decreased.
The GHRH receptor that CJC acts on does not have this problem to the same degree. Tesamorelin, which is the pharmaceutical-grade GHRH analog approved by the FDA, was studied in continuous dosing for 52 weeks in clinical trials, and IGF-1 levels that were elevated at week 26 held steady all the way through week 52 without meaningful decay. The GHRH pathway held. So the three months on, one month off cycle that most protocols use is driven entirely by protecting ghrelin receptor sensitivity, not by anything happening on the GHRH side. You are giving the GHSR1a receptors time to repopulate on the cell surface so they are responsive again when you restart.
The fourth decision is when to stop using secretagogues and move to exogenous growth hormone, and the reason this matters is that you cannot run them together effectively.
After a single injection of exogenous growth hormone, your body responds with a surge of somatostatin, which is the hormone that acts as the brake on growth hormone release. That somatostatin surge suppresses the GHRH pathway by 86 percent. Meaning the CJC-1295 you injected, which works by stimulating GHRH receptors on the pituitary, is now trying to push on a door that is almost entirely shut. You are paying for a compound that cannot do its job because the feedback system read the exogenous growth hormone and applied the brakes.
Secretagogues work within your biological ceiling. Whatever your pituitary is capable of producing at your age and health status, they optimize for that and they leave the feedback loop running. Exogenous growth hormone bypasses that ceiling and turns off the feedback loop to compensate. These are not two versions of the same approach. They are two fundamentally different interventions with different tradeoffs.
If the ceiling your pituitary can reach is enough to accomplish your goal, secretagogues are the cleaner path because you preserve normal regulatory biology. If your goal requires more growth hormone than your body can produce regardless of how well the system is optimized, then the secretagogue framework stops being relevant and you switch entirely. There is no hybrid that captures both, because the somatostatin response to exogenous growth hormone makes the CJC component functionally inactive.
The pituitary does not distinguish between a sophisticated protocol and a simple one. It responds to signals, and it uses feedback to regulate itself. Every decision in this stack either works with that biology or works around it.
References
- FDA Prescribing Information. EGRIFTA (tesamorelin). 2025 — 52-week continuous dosing, IGF-1 levels maintained at week-26 levels through week 52
- Bowers CY et al. On the in vitro and in vivo activity of a new synthetic hexapeptide. Endocrinology. 1984 — GHRP/ghrelin receptor agonist mechanism
- PNAS. Discovery of a functionally selective ghrelin receptor (GHSR1a) ligand. 2022 — β-arrestin mediated GHSR1a desensitization mechanism
- Veldhuis JD et al. Somatostatin inhibition of GHRH-stimulated GH secretion. J Clin Endocrinol Metab — 86% GHRH pathway inhibition after exogenous GH
- Falutz J et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. NEJM. 2007 — Tesamorelin 26-week clinical trial efficacy
Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness
If this is the kind of information you want access to on a daily basis, the community is free and there are full courses on training, nutrition, hormones, and supplementation inside. You can ask questions and post your own labs and get feedback from me and from the community.